Literature DB >> 10492185

Immediate and postoperative complications of transurethral prostatectomy in the 1990s.

P G Borboroglu1, C J Kane, J F Ward, J L Roberts, J P Sands.   

Abstract

PURPOSE: We compare the morbidity, mortality, hospitalization and urethral catheter time of contemporary transurethral prostatectomy to historical series, and evaluate recent trends in hospitalization and urethral catheter time during the last 8 years.
MATERIALS AND METHODS: A retrospective chart review of 520 consecutive patients who underwent transurethral prostatectomy between 1991 and 1998 at a single institution for symptomatic benign prostatic hyperplasia was performed. Inpatient and outpatient charts, clinic records, operative reports and discharge summaries were reviewed. For each patient 43 data points were collected. Telephone followup was performed when data were lacking. All retrieved data were compiled in a computer database. Perioperative and late postoperative morbidity and mortality, hospitalization and urethral catheter time were analyzed.
RESULTS: A total of 520 patients were identified with an average age of 67 years (range 44 to 89). Significant co-morbidity (2 or more co-morbid disease processes) was identified preoperatively in 30.3% of the patients. The most common indications for transurethral prostatectomy were lower urinary tract symptoms (80.9%) and urinary retention (15.2%). Average preoperative International Prostate Symptom Score was 23.8. Average weight of resected tissue was 18.8 gm. There was no perioperative patient mortality. Blood transfusion rate was 0.4%. The rate of intraoperative and immediate postoperative complications was 2.5% and 10.8%, respectively. Average hospital stay was 2.4 days, and 1.1 from 1997 through 1998. The rate of late postoperative complication was 8.5% and the average postoperative symptom score was 6.4 with an average followup of 42 months (range 6 to 84).
CONCLUSIONS: Contemporary perioperative and postoperative complications of transurethral prostatectomy are significantly lower than rates in historical series. The average hospital stay and urethral catheter time have steadily decreased during the last 8 years.

Entities:  

Mesh:

Year:  1999        PMID: 10492185

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

1.  Ascites following prostatectomy: a rare presentation of comorbid disease.

Authors:  Güven Aslan; Müjde Soytürk; Aykut Kefi; Ilhan Celebi; Hale Akpinar
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 2.  Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy.

Authors:  Julien Berger; Gregoire Robert; Aurelien Descazeaud
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

3.  Greenlight high-performance system (HPS) 120-W laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a meta-analysis of the published results of randomized controlled trials.

Authors:  Yan Zhou; Boxin Xue; Nadeem Ahmed Mohammad; Dong Chen; Xiaofei Sun; Jinhui Yang; Guangcheng Dai
Journal:  Lasers Med Sci       Date:  2016-02-11       Impact factor: 3.161

4.  Impact of oral anticoagulation on morbidity of transurethral resection of the prostate.

Authors:  Aurélien Descazeaud; Gregoire Robert; Souhil Lebdai; Alain Bougault; Abdel Rahmene Azzousi; Olivier Haillot; Marian Devonec; Marc Fourmarier; Christian Saussine; Nicolas Barry-Delongchamps; Alexandre de la Taille
Journal:  World J Urol       Date:  2010-06-25       Impact factor: 4.226

Review 5.  Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis of randomized controlled trials.

Authors:  Ya-Chen Zang; Xin-Xi Deng; Dong-Rong Yang; Bo-Xin Xue; Li-Jun Xu; Xiao-Long Liu; Yi-Bin Zhou; Yu-Xi Shan
Journal:  Lasers Med Sci       Date:  2015-12-28       Impact factor: 3.161

6.  A multicentre single-blind randomized controlled trial comparing bipolar and monopolar transurethral resection of the prostate.

Authors:  Carlos E Méndez-Probst; Linda Nott; Stephen E Pautler; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

Review 7.  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.

Authors:  Christopher J Dunn; Anna Matheson; Diana M Faulds
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  Photoselective green-light laser vaporisation vs. TURP for BPH: meta-analysis.

Authors:  Hui Ding; Wan Du; Ze-Ping Lu; Zhen-Xing Zhai; Han-Zhang Wang; Zhi-Ping Wang
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

9.  [Thulium:YAG vaporesection of the prostate. First results].

Authors:  T Bach; T R W Herrmann; R Ganzer; A Blana; M Burchardt; A J Gross
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

Review 10.  Laser treatment of symptomatic benign prostatic hyperplasia.

Authors:  Ehab A Elzayat; Mostafa M Elhilali
Journal:  World J Urol       Date:  2006-03-04       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.